Drug – bio-affecting and body treating compositions – Solid synthetic organic polymer as designated organic active... – Aftertreated polymer
Reexamination Certificate
2006-06-06
2006-06-06
Kishore, Gollamudi S. (Department: 1615)
Drug, bio-affecting and body treating compositions
Solid synthetic organic polymer as designated organic active...
Aftertreated polymer
C424S078260, C424S078270
Reexamination Certificate
active
07056500
ABSTRACT:
The invention provides polymer conjugates of opioid antagonists comprising a polymer, such as poly(ethylene glycol), covalently attached to an opioid antagonist. The linkage between the polymer and the opioid antagonist is preferably hydrolytically stable. The invention also includes a method of treating one or more side effects associated with the use of opioid analgesics, such as constipation, nausea, or pruritus, by administering a polymer conjugate of the invention.
REFERENCES:
patent: 4366159 (1982-12-01), Magruder
patent: 4670417 (1987-06-01), Iwasaki et al.
patent: 4719215 (1988-01-01), Goldberg
patent: 4730048 (1988-03-01), Portoghese
patent: 4806556 (1989-02-01), Portoghese
patent: 4861781 (1989-08-01), Goldberg
patent: 5053228 (1991-10-01), Mori et al.
patent: 5102887 (1992-04-01), Goldberg
patent: 5159081 (1992-10-01), Cantrell et al.
patent: 5225206 (1993-07-01), Fushimi et al.
patent: 5250542 (1993-10-01), Cantrell et al.
patent: 5270328 (1993-12-01), Cantrell et al.
patent: 5434171 (1995-07-01), Frank et al.
patent: 5567422 (1996-10-01), Greenwald
patent: 5618926 (1997-04-01), Salamone et al.
patent: 5866164 (1999-02-01), Kuczynski et al.
patent: 5972954 (1999-10-01), Foss et al.
patent: 6362254 (2002-03-01), Harris et al.
patent: 6419959 (2002-07-01), Walter et al.
patent: 6451806 (2002-09-01), Farrar
patent: 6515100 (2003-02-01), Harris
patent: WO 93/24476 (1993-12-01), None
patent: WO 96/21469 (1996-07-01), None
patent: WO 99/45964 (1999-09-01), None
patent: WO 03/051113 (2003-06-01), None
patent: WO 03/079972 (2003-10-01), None
patent: WO 03/101476 (2003-12-01), None
Olde et al., Neuroscience 1985 pp. 1247-1253.
Batz et al. Arzneimittel-Forshung 1977 pp. 1884-1888 (both the original German document and the English translation are attached).
Johansson et al., “Effect of some poly(ethylene glycol)-bound and dextran-bound affinity ligands on the partition of synaptic membranes in aqueous two-phase systems”,J. Chromatogr. B, 1994, pp. 137-147, vol. 652.
Lapicque et al., “Polysaccharidic Prodrugs for Enzymatically Controlled Release”,Journal of Controlled Release, 1986, pp. 39-45, vol. 4.
Mahkam et al., “Preparation of new biodegradable polyurethanes as a therapeutic agent”,Polymer Degradation and Stability, 2003, pp. 199-202, vol. 80.
Bennett et al., “Drug-Coupled Poly(Amino Acids) as Polymeric Prodrugs”,Journal of Bioactive and Compatible Polymers, 1988, pp. 44-52, vol. 3.
Li et al., “Poly(α-Amino Acid)-Drug Conjugates-A Biodegradable Injectable Drug Delivery System”,Polymer Preprints(American Chemical Society, Division of Polymer Chemistry), 1990, pp. 198-199, vol. 21, No. 2.
Bennett et al., “Biodegradable Polymeric Prodrugs of Naltrexone”,Journal of Controlled Release, 1991, pp. 43-52, vol. 16, Nos. 1/2.
Zalipsky, Samuel., “Chemistry of Polyethylene Glycol Conjugates with Biologically Active Molecules”,Advanced Drug Delivery Reviews, 1995, pp. 157-182, vol. 16.
Asai et al., “Naloxone Inhibits Gastric Emptying in the Rat”,Anesth. Analg.,1999, pp. 204-208, vol. 88.
Jiang et al., “Stereochemical Studies on Medicinal Agents. 23.1Synthesis and Biological Evaluation of 6-Amino Derivatives of Naloxone and Naltrexone”,J. Medicinal Chemistry, 1977, pp. 1100-1103, vol. 20, No. 8.
Negishi et al., “Coupling of Naltrexone to Biodegradable Poly(α-Amino Acids)”,Pharmaceutical Research, 1987, pp. 305-310, vol. 4, No. 4.
Olde et al., “Affinity Partitioning and Centrifugal Counter-Current Distribution of Membrane-Bound Opiate Receptors Using Naloxone-Poly(Ethylene Glycol)”,Neuroscience, 1985, pp. 1247-1253, vol. 15, No. 4.
Pasternak et al., “Macromolecular Naloxone: A Novel Long-Acting Polymer-Bound Drug”,Life Sciences, 1976, pp. 977-982, vol. 18.
Sidman et al., “Use of Synthetic Polypeptides in the Preparation of Biodegradable Delivery Systems for Narcotic Antagonists”,Synthetic Polypeptide Systems, 1980, pp. 214-231.
Fishman, J., et al., “Preparation and Evaluation of a Sustained Naloxone Delivery System in Rats”,Pharmacology, 1975, pp. 513-519, vol. 13(6).
Greenwald, R., et al., “Highly Water Soluble Taxol Derivatives: 7-Polyethylene Glycol Carbamates and Carbonates”,J. Org. Chem., 1995, pp. 331-336, vol. 60.
Harris, J. M., ed., “Poly(Ethylene Glycol) Chemistry—Biotechnical and Biomedical Applications,” 1992, pp. 1-10, Plenum Press, New York.
Takahashi, R.N., et al., “Effects of Ketamine on Nociception and Gastrointestinal Motility in Mice Are Unaffected by Naloxone,”pGen. Pharmac.,1987, pp. 201-203, vol. 18(2), Pergamon Journals Ltd.
Yolles, S., et al., “Long Acting Delivery Systems for Narcotic Antagonists II: Release Rates of Naltrexone from Poly(lactic Acid) Composites,”Journal of Pharmaceutical Sciences, Feb. 1975, pp. 348-349, vol. 64(2).
Zalipsky, S., “Functionalized Poly(ethylene glycol) for Preparation of Biologically Relevant Conjugates,”Bioconjugate Chem.,1995, pp. 150-165, vol. 6, American Chemical Society, USA.
Bentley Michael David
Cheng Lin
Roberts Michael James
Shen Xiaoming
Kishore Gollamudi S.
Nektar Therapeutics AL, Corporation
Silverman Eric E.
LandOfFree
Polymer conjugates of opioid antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polymer conjugates of opioid antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polymer conjugates of opioid antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3631250